ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 5 of 29 for:    amyotrophic lateral sclerosis duke

Neuromuscular Ultrasound in ALS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01785550
Recruitment Status : Completed
First Posted : February 7, 2013
Last Update Posted : March 11, 2015
Sponsor:
Information provided by (Responsible Party):
Duke University

Brief Summary:

Amyotrophic Lateral Sclerosis (ALS) is a progressive fatal neurodegenerative disease affecting motor neurons. Early diagnosis is essential for the success of clinical trials and objective biomarkers are needed for monitoring disease progression. Nerve and muscle ultrasound may provide this information.

This study will collect pilot data to evaluate the value of muscle and nerve ultrasound to identify and monitor disease progression in ALS.


Condition or disease Intervention/treatment
ALS Other: Ultrasound of nerve and muscle

Study Type : Observational
Actual Enrollment : 40 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Ultrasonography in Amyotrophic Lateral Sclerosis as a Predictor of Disease Progression and Tool in Diagnosis: a Pilot Study
Study Start Date : February 2013
Actual Primary Completion Date : March 2015
Actual Study Completion Date : March 2015


Group/Cohort Intervention/treatment
Control Group
No intervention to be performed.
Ultrasound Group
All will receive nerve and muscle ultrasound.
Other: Ultrasound of nerve and muscle
Ultrasound of 6 muscles and 2 nerves will be performed.




Primary Outcome Measures :
  1. Abnormalities at onset: Ultrasound vs. Electromyography [ Time Frame: 1 year ]
    Ultrasound measures will be compared to electromyography measures at the patient's initial assessment. The number of abnormal muscles will be counted using each technique and analyzed to determine if one test is superior.


Secondary Outcome Measures :
  1. Ultrasound Predicting Outcome at 1 year [ Time Frame: 1.5 years ]
    The initial ultrasound measures and patient outcomes, as measured by standard validated scales, will be assessed at periodic intervals for one year. Analysis will be performed to determine if ultrasound measures can predict the clinical course.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
All patients referred to the electromyography laboratory for ALS.
Criteria

Inclusion Criteria:

  • Subjects referred to the electromyography laboratory for ALS.

Exclusion Criteria:

  • Patients with known comorbid myopathy or neuropathy will be excluded from the study.
  • Patients unable to provide their own consent will be excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01785550


Locations
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
Duke University

Responsible Party: Duke University
ClinicalTrials.gov Identifier: NCT01785550     History of Changes
Other Study ID Numbers: Pro00042025
First Posted: February 7, 2013    Key Record Dates
Last Update Posted: March 11, 2015
Last Verified: March 2015

Additional relevant MeSH terms:
Amyotrophic Lateral Sclerosis
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
Motor Neuron Disease
Neurodegenerative Diseases
TDP-43 Proteinopathies
Neuromuscular Diseases
Proteostasis Deficiencies
Metabolic Diseases